ECLIPSE CLINICAL TECHNOLOGIES
Eclipse Clinical Technologies is a clinical informatics company headquartered in Dublin with offices in the US and continental
Europe. Eclipse provides multilingual clinical data collection, management, and statistical analysis services to the pharmaceutical,
biotechnology, and medical device sectors.
Investment: €2.5m ($2.9 million)
Source: Seroba BioVentures, Enterprise Ireland and a syndicate of Irish investors.
Fluorocap is commercializing a new and more-efficient biochip for use by the biotech and life sciences industries. A basic
prototype has been developed that provides a 20-fold improvement on current biochip technology. A review of potential customers
for the completed product has indicated strong interest in commercial exploitation of the next prototype.
Web site: http://
GAS SENSOR SOLUTIONS LIMITED
This company has a strong portfolio of innovative gas sensor technologies to solve unmet needs across a wide range of valuable
applications, including packaging permeability testing, food quality, oxygen sensitive package integrity, as well as medical
and environmental analysis.
GENABLE TECHNOLOGIES LTD.
Genable has developed an innovative technology for the suppression and replacement of genes. It is potentially applicable
to a broad range of dominant-negative genetic diseases, all of which are incurable today. Its lead program has recently completed
a proof-of-principle study in retinitis pigmentosa, an eye disease that causes blindness.
Investment: Raised €1.1 million ($1.3 million) in an investment round led by Delta Partners.
MERRION BIOPHARM LIMITED
Merrion is a specialty pharmaceutical company based on proprietary technologies for oral drug delivery acquired from the Elan
Corporation in 2003. Merrion has multiple market-ready, advanced oral drug delivery technologies with several significant
products already proven in human clinical trials.
NEUtekBio commercializes novel diagnostic and prognostic assays aimed at increasing the efficacy of critical drug treatments
involving interferons and other cytokines. The company leverages its research programs through its collaboration agreement
with the Centre National de la Recherche Scientifique in Paris.
Investment: More than €4 million ($4.7 million) over the last two years.
Source: Growcorp led a €1.8 million ($2.1 million) round; Enterprise Equity has also invested.
This drug-development company focuses on regulation of the human immune system. The company has identified a novel approach
for eliciting antigen-specific immune-suppression. Two lead products are in advanced pre-clinical studies. Opsona also has
an active interest in toll-like receptors.
Investment: €6.25 million ($7.3 million)
Source: Seroba BioVentures and a syndicate of international investors including Inventages of Switzerland and the Genen Fund (the
corporate venture arm of Genentech).